MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

Blood

Volumn 121, Issue 12, 2013, Pages 2253-2263

  Horn, Heike ^a   Ziepert, Marita ^b   Becher, Claudia ^c   Barth, Thomas F E ^d   Bernd, Heinz Wolfram ^e   Feller, Alfred C ^e   Klapper, Wolfram ^f   Hummel, Michael ^g   Stein, Harald ^g   Hansmann, Martin Leo ^h   Schmelter, Christopher ⁱ   Möller, Peter ^d   Cogliatti, Sergio ^j   Pfreundschuh, Michael ^k   Schmitz, Norbert ^l   Trümper, Lorenz ^m   Siebert, Reiner ^c   Loeffler, Markus ^b   Rosenwald, Andreas ⁱ   Ott, German ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY HOSPITAL FRANKFURT   (Germany)

ⁱ UNIVERSITY OF WÜRZBURG   (Germany)

^j CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^k SAARLAND UNIVERSITY   (Germany)

^l DEPARTMENT OF CARDIOLOGY   (Germany)

^m UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON REGULATORY FACTOR 4; KI 67 ANTIGEN; MYC PROTEIN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT; BCL6 PROTEIN, HUMAN; DNA BINDING PROTEIN; MONOCLONAL ANTIBODY; TUMOR MARKER; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME BANDING PATTERN; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CONTROLLED STUDY; DIFFUSE LARGE B CELL LYMPHOMA; EVENT FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTERNATIONAL PROGNOSTIC INDEX; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; EVALUATION; GENE EXPRESSION REGULATION; GENETICS; LARGE CELL LYMPHOMA; MIDDLE AGED; MORTALITY; MULTICENTER STUDY (TOPIC); ONCOGENE MYC; PHYSIOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DNA-BINDING PROTEINS; DOXORUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PREDNISONE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

MLCS; MLOWN;

EID: 84878030010     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-435842     Document Type: Article

References (40)

1. Swerdlow SH, Campo E, Harris NL, et al. eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer Press; 2008.
2. Rosenwald A, Wright G, Chan WC, et al. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25): 1937-1947.
3. Lenz G, Wright G, Dave SS, et al. Lymphoma/ Leukemia Molecular Profiling ProjectStromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313-2323.
4. Ott G, Ziepert M, Klapper W, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood. 2010;116(23): 4916-4925.
5. Salles G, de Jong D, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood. 2011;117(26):7070-7078.
6. Barrans SL, O’Connor SJ, Evans PA, et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol. 2002;117(2):322-332.
7. Barrans SL, Evans PA, O’Connor SJ, et al. The t (14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res. 2003;9(6): 2133-2139.
8. van Imhoff GW, Boerma EJ, van der Holt B, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(25):4135-4142.
9. Iqbal J, Greiner TC, Patel K, et al. Leukemia/ Lymphoma Molecular Profiling ProjectDistinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia. 2007; 21(11):2332-2343.
10. Yoon SO, Jeon YK, Paik JH, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology. 2008;53(2):205-217.
11. Klapper W, Stoecklein H, Zeynalova S, et al. German High-Grade Non-Hodgkin’s Lymphoma Study GroupStructural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Leukemia. 2008;22(12): 2226-2229.
12. Hummel M, Bentink S, Berger H, et al. Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche KrebshilfeA biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419-2430.
13. Barrans SL, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360-3365.
14. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533-3537.
15. Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34(3): 327-340.
16. Leucci E, Cocco M, Onnis A, et al. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol. 2008; 216(4):440-450.
17. Onnis A, De Falco G, Antonicelli G, et al. Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma. PLoS ONE. 2010;5(9):e12960.
18. Stasik CJ, Nitta H, Zhang W, et al. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica. 2010;95(4):597-603.
19. Gurel B, Iwata T, Koh CM, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol. 2008;21(9):1156-1167.
20. Ruzinova MB, Caron T, Rodig SJ. Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation. Am J Surg Pathol. 2010;34(6): 882-891.
21. Green TM, Nielsen O, de Stricker K, et al. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol. 2012;36(4): 612-619.
22. Pfreundschuh M, Schubert J, Ziepert M, et al. German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD201 B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105-116.
23. Horn H, Schmelter C, Leich E, et al. Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica. 2011;96(9):1327-1334.
24. Ventura RA, Martin-Subero JI, Jones M, et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn. 2006; 8(2):141-151.
25. Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012; 30(28):3452-3459.
26. Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460-3467.
27. Bernd HW, Ziepert M, Thorns C, et al. German High Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL)Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma—analyses of cases from two prospective randomized clinical trials. Haematologica. 2009; 94(11):1569-1580.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
29. Ziepert M, Hasenclever D, Kühnt E, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD201 B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373-2380.
30. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
31. Dave SS, Fu K, Wright GW, et al. Lymphoma/ Leukemia Molecular Profiling ProjectMolecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354(23):2431-2442.
32. Akyurek N, Uner A, Benekli M, et al. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer. 2012;118(17):4173-4183.
33. Slack GW, Gascoyne RD. MYC and aggressive B-cell lymphomas. Adv Anat Pathol. 2011;18(3): 219-228.
34. Kluk MJ, Chapuy B, Sinha P, et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS ONE. 2012;7(4):e33813.
35. Testoni M, Kwee I, Greiner TC, et al. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Br J Haematol. 2011;155(2): 274–277.
36. Jazirehi AR, Huerta-Yepez S, Cheng G, et al. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-kappaB signaling pathway in non-Hodgkin’s lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res. 2005;65(1):264-276.
37. Sears R, Nuckolls F, Haura E, et al. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000;14(19): 2501-2514.
38. Tsuneoka M, Mekada E. Ras/MEK signaling suppresses Myc-dependent apoptosis in cells transformed by c-myc and activated ras. Oncogene. 2000;19(1):115-123.
39. Shachaf CM, Perez OD, Youssef S, et al. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood. 2007;110(7):2674-2684.
40. de Jong D, Rosenwald A, Chhanabhai M, et al. Lunenburg Lymphoma Biomarker ConsortiumImmunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications—a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007;25(7):805-812.